TALLAC THERAPEUTICS
Tallac Therapeutics offers next-generation immunotherapies for cancer patients. The company is based in Burlingame, California.
TALLAC THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2018-01-01
Address:
Burlingame, California, United States
Country:
United States
Website Url:
http://www.tallactherapeutics.com
Total Employee:
11+
Status:
Active
Total Funding:
88.18 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API WordPress LetsEncrypt SSL By Default Apache Wordpress Plugins
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
ALKemist Bio
ALKemist Bio provides cell treatment to cancer patients.
Ally Therapeutics
Ally Therapeutics solves the immune response barriers for gene therapy.
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Mana Therapeutics
Next-Generation Immunotherapies
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Employees Featured
Founder
Investors List
Horizon Technology Finance
Horizon Technology Finance investment in Debt Financing - Tallac Therapeutics
Matrix Partners China
Matrix Partners China investment in Series A - Tallac Therapeutics
Morningside Venture Investments
Morningside Venture Investments investment in Series A - Tallac Therapeutics
venBio Partners
venBio Partners investment in Series A - Tallac Therapeutics
MRL Ventures Fund
MRL Ventures Fund investment in Series A - Tallac Therapeutics
Lightstone Ventures
Lightstone Ventures investment in Series A - Tallac Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2023-01-19 | Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.tallactherapeutics.com Semrush global rank: 8.49 M Semrush visits lastest month: 523
- Host name: vps23885.dreamhostps.com
- IP address: 173.236.209.113
- Location: Brea United States
- Latitude: 33.9339
- Longitude: -117.8854
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 92821
More informations about "Tallac Therapeutics"
About โ Tallac Therapeutics, Inc
Dr. Janet Sim is the Vice President of Biologics Development. She has over 20 years of drug discovery research and development experience, which includes target validation, drug โฆSee details»
Tallac Therapeutics, Inc โ Landing page
Nov 3, 2023 Tallacโs novel technology allows precise conjugation of therapeutic oligo payloads, expanding beyond the conventional toxin payloads and enabling the precise and systemic delivery of next gen therapies such as CpG โฆSee details»
Tallac Therapeutics - Crunchbase Company Profile & Funding
Tallac Therapeutics offers next-generation immunotherapies for cancer patients. The company is based in Burlingame, California.See details»
Tallac Therapeutics - LinkedIn
Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallacโs pipeline of immunotherapy candidates are โฆSee details»
Science โ Tallac Therapeutics, Inc
Tallacโs novel technology allows precise conjugation of therapeutic oligo payloads, expanding beyond the conventional toxin payloads and enabling the precise and systemic delivery of next gen therapies such as CpG โฆSee details»
Tallac Therapeutics Company Profile 2024: Valuation
Tallac Therapeutics General Information Description. Operator of a biopharmaceutical company intended to provide innate and adaptive immunity to fight cancer. The company develops conjugates of antibodies and a potent toll โฆSee details»
Tallac Therapeutics Announces FDA Clearance of ... - Business Wire
May 19, 2022 For more information, please visit www.tallactherapeutics.com. Contacts. Tallac Media Contact: Tara Cooper The Grace Communication Group (650) 303-7306 โฆSee details»
Tallac Therapeutics launches with $62M run by ALX Oncology vets, โฆ
Dec 1, 2020 The biotech is still early-stage, but gets off to life with a good start in terms of backing and a group of senior biotech veterans. This group includes co-founders Corey โฆSee details»
Tallac Therapeutics Launches with $62 Million in Series A โฆ
Dec 1, 2020 ~ Company Founded by Experienced Leaders with Track Record of Developing Successful Next-Generation Medicines for Cancer ~ Burlingame, CA, USA, Dec 1, 2020 โฆSee details»
Tallac Therapeutics Announces Two Abstracts Accepted for โฆ
Sep 27, 2023 BURLINGAME, Calif.--(BUSINESS WIRE)--Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to โฆSee details»
Tallac Therapeutics Launches with $62 Million in Series A โฆ
Dec 1, 2020 For more information, please visit www.tallactherapeutics.com. Contacts. Tallac Media Contact: Tara Cooper The Grace Communication Group [email protected] 650-303 โฆSee details»
Tallac Therapeutics Launches with $62 Million in Series A โฆ
Dec 1, 2020 Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the completion of โฆSee details»
News โ Tallac Therapeutics, Inc
May 19, 2022 10 Apr, 2024 Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association โฆSee details»
Tallac Therapeutics Announces First Patient Dosed with TAC-001, a โฆ
Jul 28, 2022 For more information, please visit www.tallactherapeutics.com. Contacts. Tallac Media Contact: Tara Cooper The Grace Communication Group (650) 303-7306 โฆSee details»
Working at Tallac Therapeutics - Glassdoor
Glassdoor gives you an inside look at what it's like to work at Tallac Therapeutics, including salaries, reviews, office photos, and more. This is the Tallac Therapeutics company profile.See details»
Tallac Therapeutics Announces FDA Clearance of Investigational โฆ
May 19, 2022 For more information, please visit www.tallactherapeutics.com. Tallac Media Contact: Tara Cooper The Grace Communication Group (650) 303-7306 [email protected]. โฆSee details»
ALX Oncology and Tallac Therapeutics Announce Collaboration
Mar 4, 2021 Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRPฮฑ antibody conjugated to TLR9 agonist (โSIRPฮฑ...See details»
Tallac Therapeutics Presents New Data on Toll-like Receptor โฆ
Apr 10, 2021 Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody Conjugate, TAC-001, at the 2021 Virtual Annual Meeting of the American Association for โฆSee details»
ALX Oncology and Tallac Therapeutics Announce Collaboration on โฆ
Mar 4, 2021 For more information, please visit www.tallactherapeutics.com. Cautionary Note Regarding Forward-Looking Statements. This press release contains โforward-looking โฆSee details»
Tallac Presents First Clinical Data for TAC-001 at SITC 2023
Nov 3, 2023 Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today annoSee details»